Please note that the ANZCTR website will be unavailable from 6pm until 6.30pm (AEST) on Monday 22nd July for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01000506




Registration number
NCT01000506
Ethics application status
Date submitted
22/10/2009
Date registered
23/10/2009
Date last updated
24/01/2018

Titles & IDs
Public title
Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma
Scientific title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Determine the Effect of Mepolizumab on Exacerbation Rates in Subjects With Severe Uncontrolled Refractory Asthma
Secondary ID [1] 0 0
112997
Universal Trial Number (UTN)
Trial acronym
DREAM
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Asthma 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Asthma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Mepolizumab 750
Other interventions - Mepolizumab 250
Other interventions - Mepolizumab 75
Treatment: Drugs - Placebo saline

Active Comparator: Mepolizumab 750mg - Mepolizumab 750mcg i.v. every 4 weeks

Active Comparator: Mepolizumab 250mg - Mepolizumab 250mcg i.v. every 4 weeks

Active Comparator: Mepolizumab 75mg - Mepolizumab 75mcg i.v. every 4 weeks

Placebo Comparator: Placebo - Placebo saline every 4 weeks i.v.


Other interventions: Mepolizumab 750
Mepolizumab 750mg every four weeks by i.v.

Other interventions: Mepolizumab 250
Mepolizumab 250mg every four weeks by i.v.

Other interventions: Mepolizumab 75
Mepolizumab 75mg every four weeks by i.v.

Treatment: Drugs: Placebo saline
Placebo saline every four weeks by i.v.

Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Clinically Significant Exacerbations of Asthma Per Year - Clinically significant exacerbations of asthma are defined as worsening of asthma which required use of oral/systemic corticosteroids (for participants on maintenance oral corticosteroids [OCS], an exacerbation requiring OCS is defined as the use of oral/systemic corticosteroids at least double the existing maintenance dose for at least 3 days) and/or hospitalization and/or emergency department (ED) visit. The frequency of clinically significant exacerbations of asthma over the 52-week treatment period is expressed as exacerbation rate per year. Analysis of the number of exacerbations was performed using a negative binomial regression model with covariates of treatment group, Baseline (BL) maintenance OCS therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and BL percent (%) predicted forced expiratory volume in 1 second (FEV1), and with logarithm of time on treatment as an offset variable
Timepoint [1] 0 0
From randomization (Week 0) to Week 52 or early withdrawal (EW)
Secondary outcome [1] 0 0
Time to First Clinically Significant Exacerbation Requiring Oral or Systemic Corticosteroid, Hospitalization and/ or ED Visit - Clinically significant exacerbations of asthma are defined as worsening of asthma which required use of oral/systemic corticosteroids (for participants on maintenance OCS, an exacerbation requiring OCS is defined as the use of oral/systemic corticosteroids at least double the existing maintenance dose for at least 3 days) and/or hospitalization and/or ED visit. Kaplan-Meier estimates of the probability of an exacerbation is expressed as percentage of participants with an exacerbation over time (by Week 16, Week 32 and Week 52).
Timepoint [1] 0 0
From randomization (Week 0) to Week 52 or EW
Secondary outcome [2] 0 0
Number of Exacerbations Requiring Hospitalization (Including Intubation and Admittance to an Intensive Care Unit [ICU]) or ED Visit Per Year - The frequency of exacerbations of asthma requiring hospitalization (including intubation and admittance to an intensive care unit [ICU]) or ED visit over the 52-week treatment period is expressed as exacerbation rate per year. Analysis of the number of exacerbations was performed using a negative binomial regression model with covariates of treatment group, Baseline (BL) maintenance OCS therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and BL percent (%) predicted forced expiratory volume in 1 second (FEV1), and with logarithm of time on treatment as an offset variable.
Timepoint [2] 0 0
From randomization (Week 0) to Week 52 or EW
Secondary outcome [3] 0 0
Time to First Exacerbation Requiring Hospitalization or ED Visit - Exacerbations of asthma requiring hospitalization or ED visit were assessed. Kaplan-Meier estimates of the probability of an exacerbation is expressed as percentage of participants with an exacerbation over time (by Week 16, Week 32 and Week 52).
Timepoint [3] 0 0
From randomization (Week 0) to Week 52 or EW
Secondary outcome [4] 0 0
Number of All Recorded Exacerbations Per Year - Clinically significant exacerbations (ex) of asthma are defined as worsening of asthma which required use of oral/systemic corticosteroids (for par. on maintenance OCS, an ex requiring OCS is defined as the use of oral/systemic corticosteroids at least double the existing maintenance dose for at least 3 days) and/or hospitalization and/or ED visit. In the case, an event described as an ex was not associated with a deterioration in >=1 of the objectives of eDiary parameters, the investigator (inv) provided an explanation to support the decision for defining the event as an ex. All recorded ex were defined as those recorded by inv, regardless of the outcome of the ex review process. Analysis was performed using Negative Binomial regression model with covariates of treatment group, BL maintenance OCS therapy (OCS vs. no OCS), region, ex in the year prior to the study (as an ordinal variable) and BL % predicted FEV1, and with logarithm of time on treatment as an offset variable.
Timepoint [4] 0 0
From randomization (Week 0) to Week 52 or EW
Secondary outcome [5] 0 0
Time to First All Recorded Exacerbation - All recorded exacerbations are defined as those recorded by investigators, regardless of the outcome of the exacerbation review process. In the case, an event described as an exacerbation was not associated with a deterioration in at least one of the objectives of eDiary parameters, the investigator provided an explanation to support the decision for defining the event as an exacerbation. Kaplan-Meier estimates of the probability of an exacerbation is expressed as percentage of participants with an exacerbation over time (by week 16, week 32 and week 52).
Timepoint [5] 0 0
From randomization (Week 0) to Week 52 or EW
Secondary outcome [6] 0 0
Mean Change From Baseline in Clinic Pre-bronchodilator FEV1 Over the 52-week Treatment Period - FEV1 is defined as the volume of air forcefully expelled from the lungs in 1 second. Pre-bronchodilator FEV1 measurements were taken by spirometry at each clinic visit. The change from Baseline is defined as the difference between the value of the endpoint at the time point of interest and the Baseline value. Analysis was performed using mixed model repeated measures with covariates of Baseline, region, Baseline maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable), treatment and visit, plus interaction terms for visit by Baseline and visit by treatment group.
Timepoint [6] 0 0
From Baseline up to Week 52 or EW
Secondary outcome [7] 0 0
Mean Change From Baseline in Clinic Post-bronchodilator FEV1 Over the 52-week Treatment Period - FEV1 is defined as the volume of air forcefully expelled from the lungs in 1 second. Post-bronchodilator FEV1 measurements were taken by spirometry at Baseline, Week 16, Week 32 and Week 52. Post bronchodilator values were recorded following reversibility testing, using the maximum post bronchodilator method. Participants unable to achieve >=12% reversibility and 200 mL change at Visit 1, reversibility test was repeated at Visit 2. These procedures to achieve the maximum post-bronchodilator are generated by the Asthma Clinical Research Network. The change from Baseline is defined as the difference between the value of the endpoint at the time point of interest and the Baseline value. Analysis was performed using mixed model repeated measures with covariates of Baseline, region, Baseline maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable), treatment and visit, plus interaction terms for visit by Baseline and visit by treatment
Timepoint [7] 0 0
From Baseline up to Week 52 or EW
Secondary outcome [8] 0 0
Mean Change From Baseline in Asthma Control Questionnaire (ACQ) Score Over the 52-week Treatment Period - The ACQ-6 is a six-item questionnaire. The six questions enquire about the frequency and/or severity of symptoms (nocturnal awakening on waking in the morning, activity limitation, shortness of breath, wheeze) and use of short-acting bronchodilator over the previous week. The response options for all these questions consist of a 0 (no impairment/limitation) to 6 (total impairment/ limitation) scale. The overall ACQ score is calculated as the mean of the 6 questions and therefore ranges between 0 (totally controlled) and 6 (severely uncontrolled). Change from BL is defined as the difference between the value of the endpoint at the time point of interest and BL value. Analysis was performed using mixed model repeated measures with covariates of BL, region, BL maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable), BL % predicted FEV1, treatment and visit, plus interaction terms for visit by BL and visit by treatment group.
Timepoint [8] 0 0
From Baseline up to Week 52 or EW

Eligibility
Key inclusion criteria
- Male or female

- Aged 12 to 65 years inclusive

- Minimum weight 45kg

- Clinical features of severe refractory asthma

- Well documented requirement for high dose inhaled corticosteroids (ICS) [i.e. >=
880mcg/day fluticasone propionate or equivalent daily] for at least 12 months

- Using additional controller medication in addition to high dose ICS for at least 12
months

- Persistent airflow obstruction indicated by a pre-bronchodilator FEV1<80% predicted at
visit 1 or 2 or peak flow diurnal variability of >20% on 3 or more days during the
run-in

- Airway inflammation which is likely to be eosinophilic in nature demonstrated by
either raised peripheral blood eosinophils (>=300/microL), sputum eosinophils (>=3%),
exhaled nitric oxide (>=50ppb) or prompt deterioration of asthma control following a
<=25% reduction in regular maintenance dose of inhaled or oral corticosteroids (OCS)

- History of 2 or more exacerbations requiring systemic corticosteroids in the previous
12 months

- Evidence of asthma documented by airway reversibility, airway hyperresponsiveness or
airflow variability

- ECG assessment demonstrating QTc<450msec or QTc<480msec for patients with bundle
branch block

- Liver function tests demonstrating ALT<2xUpper Limit of Normal (ULN), AST<2xULN, Alk
Phos <=1.5xULN, bilirubin <=1.5xULN

- Female of non-child-bearing potential or child-bearing potential with a negative
pregnancy test at screening and prepared to agree to an acceptable method of
contraception

- Able to give written informed consent

- Able to read, comprehend and write at a sufficient level to complete study materials
Minimum age
12 Years
Maximum age
65 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Current smokers or smoking history of >=10 pack years

- Clinically important lung condition other than asthma

- Diagnosis of malignancy or in the process of investigation

- Unstable liver disease

- Churg-Strauss syndrome

- Using methotrexate, troleandomycin, oral gold, cyclosporine, azathioprine or any
experimental anti-inflammatory therapy within 3 months of screening

- Omalizumab (Xolair) or any other biological for the treatment of inflammatory disease
within 6 months of Visit 1

- Regular use of oral or systemic corticosteroids for diseases other than asthma within
12 months or any intra-articular, short-acting intramuscular corticosteroid within 1
month or intramuscular, long-acting depot corticosteroid within 3 months

- Allergy/intolerance to the excipients in the mepolizumab formulation

- Any investigational drug within 30 days or 5 terminal half-lives, whichever is longer

- Pregnant or breastfeeding or planning to become pregnant

- Clinically significant disease which is uncontrolled with standard treatment

- History of alcohol misuse or substance abuse

- Parasitic infestation within previous 6 months

- Known immunodeficiency

- Unable to follow instructions, use the electronic diary or peak flow meter

- Known evidence of lack of adherence to controller medications and/or follow
physician's recommendations

- Previous participation in a study of mepolizumab and received study medication within
90 days

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
GSK Investigational Site - New Lambton
Recruitment hospital [2] 0 0
GSK Investigational Site - Adelaide
Recruitment hospital [3] 0 0
GSK Investigational Site - Clayton
Recruitment hospital [4] 0 0
GSK Investigational Site - Melbourne
Recruitment hospital [5] 0 0
GSK Investigational Site - Nedlands
Recruitment postcode(s) [1] 0 0
2305 - New Lambton
Recruitment postcode(s) [2] 0 0
5000 - Adelaide
Recruitment postcode(s) [3] 0 0
3168 - Clayton
Recruitment postcode(s) [4] 0 0
3004 - Melbourne
Recruitment postcode(s) [5] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Kentucky
Country [6] 0 0
United States of America
State/province [6] 0 0
Missouri
Country [7] 0 0
United States of America
State/province [7] 0 0
North Carolina
Country [8] 0 0
United States of America
State/province [8] 0 0
Ohio
Country [9] 0 0
United States of America
State/province [9] 0 0
Oklahoma
Country [10] 0 0
United States of America
State/province [10] 0 0
Pennsylvania
Country [11] 0 0
United States of America
State/province [11] 0 0
South Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Tennessee
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
United States of America
State/province [14] 0 0
Wisconsin
Country [15] 0 0
Argentina
State/province [15] 0 0
Buenos Aires
Country [16] 0 0
Argentina
State/province [16] 0 0
Ciudad Autónoma de Buenos Aires
Country [17] 0 0
Argentina
State/province [17] 0 0
Mendoza
Country [18] 0 0
Argentina
State/province [18] 0 0
Tucuman
Country [19] 0 0
Canada
State/province [19] 0 0
Alberta
Country [20] 0 0
Canada
State/province [20] 0 0
British Columbia
Country [21] 0 0
Canada
State/province [21] 0 0
Ontario
Country [22] 0 0
Canada
State/province [22] 0 0
Quebec
Country [23] 0 0
Chile
State/province [23] 0 0
Región Metro De Santiago
Country [24] 0 0
Chile
State/province [24] 0 0
Valparaíso
Country [25] 0 0
Chile
State/province [25] 0 0
Santiago
Country [26] 0 0
Chile
State/province [26] 0 0
Talcahuano
Country [27] 0 0
France
State/province [27] 0 0
Clamart
Country [28] 0 0
France
State/province [28] 0 0
Marseille cedex 20
Country [29] 0 0
France
State/province [29] 0 0
Montpellier
Country [30] 0 0
France
State/province [30] 0 0
Nantes
Country [31] 0 0
France
State/province [31] 0 0
Saint Pierre cedex
Country [32] 0 0
Germany
State/province [32] 0 0
Brandenburg
Country [33] 0 0
Germany
State/province [33] 0 0
Hessen
Country [34] 0 0
Germany
State/province [34] 0 0
Rheinland-Pfalz
Country [35] 0 0
Germany
State/province [35] 0 0
Sachsen-Anhalt
Country [36] 0 0
Germany
State/province [36] 0 0
Schleswig-Holstein
Country [37] 0 0
Germany
State/province [37] 0 0
Berlin
Country [38] 0 0
Korea, Republic of
State/province [38] 0 0
Bucheon-si,
Country [39] 0 0
Korea, Republic of
State/province [39] 0 0
Cheongju, Chungcheongbuk-do
Country [40] 0 0
Korea, Republic of
State/province [40] 0 0
Seoul
Country [41] 0 0
Korea, Republic of
State/province [41] 0 0
Suwon, Kyonggi-do
Country [42] 0 0
Poland
State/province [42] 0 0
Bialystok
Country [43] 0 0
Poland
State/province [43] 0 0
Lodz
Country [44] 0 0
Poland
State/province [44] 0 0
Warszawa
Country [45] 0 0
Poland
State/province [45] 0 0
Wroclaw
Country [46] 0 0
Poland
State/province [46] 0 0
Zawadzkie
Country [47] 0 0
Poland
State/province [47] 0 0
Zgierz
Country [48] 0 0
Romania
State/province [48] 0 0
Bucharest
Country [49] 0 0
Romania
State/province [49] 0 0
Bucuresti
Country [50] 0 0
Romania
State/province [50] 0 0
Iasi
Country [51] 0 0
Romania
State/province [51] 0 0
Targu Mures
Country [52] 0 0
Russian Federation
State/province [52] 0 0
Barnaul
Country [53] 0 0
Russian Federation
State/province [53] 0 0
Chelyabinsk
Country [54] 0 0
Russian Federation
State/province [54] 0 0
Kazan
Country [55] 0 0
Russian Federation
State/province [55] 0 0
Moscow
Country [56] 0 0
Russian Federation
State/province [56] 0 0
Saint-Petersburg
Country [57] 0 0
Russian Federation
State/province [57] 0 0
St. Petersburg
Country [58] 0 0
Russian Federation
State/province [58] 0 0
Tomsk
Country [59] 0 0
Ukraine
State/province [59] 0 0
Cherkassy
Country [60] 0 0
Ukraine
State/province [60] 0 0
Dnipropetrovsk
Country [61] 0 0
Ukraine
State/province [61] 0 0
Donetsk
Country [62] 0 0
Ukraine
State/province [62] 0 0
Kharkiv
Country [63] 0 0
Ukraine
State/province [63] 0 0
Kiev
Country [64] 0 0
Ukraine
State/province [64] 0 0
Kyiv
Country [65] 0 0
Ukraine
State/province [65] 0 0
Mykolayiv
Country [66] 0 0
United Kingdom
State/province [66] 0 0
Leicestershire
Country [67] 0 0
United Kingdom
State/province [67] 0 0
London
Country [68] 0 0
United Kingdom
State/province [68] 0 0
Manchester
Country [69] 0 0
United Kingdom
State/province [69] 0 0
Southampton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously
(i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma
despite receiving high doses of standard asthma medications. The study will look at different
doses of mepolizumab in comparison to a placebo.
Trial website
https://clinicaltrials.gov/show/NCT01000506
Trial related presentations / publications
Pavord I, Korn S, Howarth P, Bleecker E, Buhl R, Keene O, Ortega H, Chanez P. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. [Lancet]. 2012;380(August 18, 2012):
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications